Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.32 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.32 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744717 | 0.74 | RBP4 (0.32) | RBP4MKNK1NPC1RAB9A | |
| SCHEMBL25658370 | 0.74 | RBP4 (0.32) | RBP4MKNK1 | |
| SCHEMBL3122117 | 0.74 | PDE4A (0.34) | RBP4MKNK1PDE4APDE4BPDE4C | |
| SCHEMBL2066959 | 0.74 | DYRK1A (0.47) | PDE10ARBP4MKNK1PDE4APDE4B | |
| SCHEMBL2066202 | 0.74 | NPC1 (0.37) | RBP4MKNK1NPC1RAB9A | |
| SCHEMBL26373813 | 0.74 | RBP4 (0.32) | RBP4MKNK1PDE4A | |
| SCHEMBL9935117 | 0.74 | RBP4 (0.32) | RBP4MKNK1 | |
| SCHEMBL876570 | 0.74 | KLKB1 (0.33) | RBP4NPC1RAB9A | |
| SCHEMBL1499196 | 0.74 | RBP4 (0.40) | PDE10ARBP4PDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL23290947 | 0.72 | DYRK1A (0.46) | PDE10ARBP4MKNK1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4490162-A1 | PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-01-15 | — | — | EP | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023170115-A1 | PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-14 | — | — | WO | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-2300469-B1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-1932846-B1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20100234597-A1 | PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| WO-2010033941-A1 | SUBSTITUTED IMIDAZO[1,2B]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | disclosed |
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1932846-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1930331-A1 | METHOD FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-0381132-A1 | Imidazopyridazines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SALL4, CLCN2, CLIC1 | PDE10A 3486/4885RBP4 718/4885KCNN1 174/4885 |
| US-20100234597-A1 | PROCESS FOR PRODUCING IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CYP1B1, CYP4Z1, CYP2J2 | PDE10A 2514/4885RBP4 1653/4885KCNN1 259/4885 |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | HNRNPR, HNRNPAB, RBM3 | PDE10A 4530/4885RBP4 298/4885KCNN1 4613/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | PDE10A 4530/4885RBP4 298/4885KCNN1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.